Clinical Trials
4 trialsNCT04924062 2026-04-15
KEYNOTE-966
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04003636 2026-03-24
KEYNOTE-966
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT05849480 2026-03-24
A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT05346484 2026-03-06
MAST
Imugene Limited
Phase 1 Terminated